ADVI Perspectives: IRA Implementation and “Government Negotiation”
Lindsay Bealor Greenleaf, JD, MBA
September 15, 2023
President Biden’s announcement on the first ten drugs targeted for “government negotiation” under the Inflation Reduction Act (IRA) is set to shake up the pharmaceutical landscape.
ADVI expert Lindsay Bealor Greenleaf, vice president and head of policy, shared insights on why this is one of the biggest key policy reforms of the moment.
Listen Now
Hear more from Lindsay on what’s to come for the IRA and provide an in-depth analysis of the highly anticipated government negotiation.
Key Policy Reform and Impacts to Consider for 2023 / 2024
Learn More
Stay ahead of the curve. Get in touch today to gain expert insights into the IRA and the evolving healthcare landscape.
Lindsay Bealor Greenleaf, JD, MBA
Senior Vice President, Market Access and Policy Strategy
CEO insights
Related articles
Real analysis from people who’ve been there
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption
Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …
Marc Samuels, JD, MPH
December 30, 2025
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
What HEOR Information Does CMS Need for Drug Price Negotiations Under the IRA?
As the Inflation Reduction Act (IRA) reshapes drug pricing policy in the United States, the Centers for Medicare and Medicaid (CMS) …
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Real-World Effectiveness vs Clinical Trial Efficacy in Medicare
The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development
Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.